Stock DNA
Pharmaceuticals & Biotechnology
USD 286 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.78
-999,999.00%
2.03
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Mar 2026)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.9%
0%
33.9%
6 Months
25.57%
0%
25.57%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Shoulder Innovations, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
56.70%
EBIT Growth (5y)
-164.94%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
41.50%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.03
EV to EBIT
-6.72
EV to EBITDA
-7.66
EV to Capital Employed
5.63
EV to Sales
3.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-83.70%
ROE (Latest)
-19.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 13 Schemes (15.7%)
Foreign Institutions
Held by 14 Foreign Institutions (3.91%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
16.70
14.40
15.97%
Operating Profit (PBDIT) excl Other Income
-7.80
-7.50
-4.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.40
-7.80
-7.69%
Operating Profit Margin (Excl OI)
-537.20%
-589.60%
5.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 15.97% vs 22.03% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -7.69% vs 10.34% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
47.30
31.60
49.68%
Operating Profit (PBDIT) excl Other Income
-23.10
-12.50
-84.80%
Interest
0.10
1.30
-92.31%
Exceptional Items
-14.20
-0.10
-14,100.00%
Consolidate Net Profit
-40.40
-15.60
-158.97%
Operating Profit Margin (Excl OI)
-555.80%
-463.40%
-9.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 49.68% vs 63.73% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -158.97% vs -22.83% in Dec 2024






